title: Duration of Adjuvant Therapy for Patients With Gastrointestinal Stromal Tumors: Where Is Goldilocks When We Need Her?
authors.affiliation: Division of Hematology-Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon.
authors.forename: Charles D
authors.initials: CD
authors.lastname: Blanke
authors.affiliation: Division of General Surgical Oncology, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York.
authors.forename: Ronald P
authors.initials: RP
authors.lastname: DeMatteo
mesh_terms: D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate / Q000627:therapeutic use*; D054539:Medication Therapy Management / Q000639:trends; D058990:Molecular Targeted Therapy
chemical_list: D000068877:Imatinib Mesylate